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Key summary points
Aim To explore the association between number of medications and mortality in geriatric inpatients when adjusted for 
diseases and activities of daily living.
Findings Increasing number of medications is associated with increased mortality. Every increase in number of medications 
by one is associated with a 3% increase in overall mortality.
Message Evaluation of polypharmacy is important part of geriatric assessment when older adults are hospitalized.
Abstract
Purpose To explore the association between the number of medications and mortality in geriatric inpatients taking activities 
of daily living and comorbidities into account.
Methods A nationwide population-based cohort study was performed including all patients aged ≥ 65 years admitted to 
geriatric departments in Denmark during 2005–2014. The outcome of interest was mortality. Activities of daily living 
using Barthel Index (BI) were measured at admission. National health registers were used to link data on an individual 
level extracting data on medications, and hospital diseases. Patients were followed to the end of study (31/12/2015), death, 
or emigration, which ever occurred first. Kaplan–Meier survival curves were used to estimate crude survival proportions. 
Univariable and multivariable analyses were performed using Cox regression. The multivariable analysis were adjusted for 
age, marital status, period of hospital admission, BMI, and BI (model 1), and additionally either number of diseases (model 
2) or Charlson comorbidity index (model 3).
Results We included 74,603 patients (62.8% women), with a median age of 83 (interquartile range [IQR] 77–88) years. 
Patients used a median of 6 (IQR 4–9) medications. Increasing number of medications was associated with increased over-
all, 30-day, and 1-year mortality in all three multivariable models for both men and women. For each extra medication, the 
mortality increased by 3% in women and 4% in men in the fully adjusted model.
Conclusion Increasing number of medications was associated with mortality in this nationwide cohort of geriatric inpatients. 
Our findings highlight the importance of polypharmacy in older patients with comorbidities.
Keywords Polypharmacy · Comorbidity · Mortality · Geriatric · Barthel · ADL
Introduction
Geriatric inpatients are characterized and challenged by the 
presence of multimorbidity, polypharmacy, and often func-
tional decline [1–3]. Between multiple factors associated 
with mortality among older inpatients [4–6], it is acknowl-
edged that one of the most important is activities of daily 
living (ADL) [7]. ADL can e.g. be measured by the Barthel 
Index, which focuses on the patient’s level of dependency in 
basic ADL. Strong correlations between Barthel Index and 
Electronic supplementary material The online version of this 
article (https ://doi.org/10.1007/s4199 9-020-00390 -3) contains 
supplementary material, which is available to authorized users.
 * Kristoffer Kittelmann Brockhattingen 
 Kristoffer.k.brockhattingen@rsyd.dk
Extended author information available on the last page of the article
 European Geriatric Medicine
1 3
mortality in geriatric patients have previously been reported 
[8, 9]. Multimorbidity and chronic diseases in general are 
also associated with mortality [10, 11], particularly the 
Charlson comorbidity Index which focuses on certain severe 
diseases [12, 13].
Recent studies have highlighted the importance of con-
sidering polypharmacy as an independent risk of hospitali-
zation and mortality because of adverse drug reactions and 
drug–drug interactions [14, 15]. Some studies have tried 
to distinguish polypharmacy from multimorbidity when 
assessing the independent influence on mortality [16, 17]. 
Although a few of these studies provided evidence that poly-
pharmacy is associated with increased mortality [18, 19], 
only a limited number of them took functional decline into 
account when assessing the association between polyphar-
macy and overall mortality [18, 20, 21].
This study aims to explore the association between the 
number of medications and mortality in older geriatric 
inpatients when adjusted for diseases and activities of daily 
living.
Methods
This was a nationwide register-based cohort study in geriat-
ric inpatients with all-cause mortality as the main outcome. 
In Denmark, each citizen is given a unique ten-digit social 
security number at birth or upon immigrating to the coun-
try. This number serves as a link to all information (e.g. 
marital status, migration, death etc.) about the individual 
[22]. We used the identification number to link data on an 
individual level from the following four Danish health reg-
isters: The Danish National Database of Geriatrics [23], The 
Danish National Patient Register [24], The Danish Civil 
Registry System [25], and the Danish National Database 
of Reimbursed Prescriptions [26]. Setting and participants 
have previously been described in detail elsewhere [8]. In 
short, the study population was identified through the Dan-
ish National Database of Geriatrics and included patients 
65 years or older with their first registration in the database 
during 2005–2014. The inclusion date was defined as the 
first date of admission to a geriatric department registered in 
the database during the study period. Patients were followed 
from the individual index date and until death, immigra-
tion, or end of study on December 31st 2015, allowing up to 
10 years of follow-up, depending on the time of admission.
Data on prescription medicine purchased 120 days prior 
to index date were extracted from the Danish National Data-
base of Reimbursed Prescriptions. A cut-off of 120 days was 
chosen since the majority of medications for long-term treat-
ment are administered in 100-pill packages in Denmark [27]. 
Anatomical therapeutic chemical (ATC) codes were counted 
at the fourth level to classify and quantify medications and 
numbers of prescribed medications were grouped into four 
categories: 0, 1–4, 5–9, or ≥ 10.
Information regarding any prior hospitalizations, dates 
of admission and discharge, and diagnoses were collected 
from the Danish National Patient Register. The total num-
ber of diseases was calculated using the ICD-10 hospital 
discharge and outpatient diagnoses 10 years prior to the 
index dates. The ICD-10 diagnosis was discriminated 
at the third level of the ICD-10 code. To avoid exces-
sive scores for disease, the same diagnoses only counted 
once. Diagnoses were grouped in four categories 0, 1–9, 
10–19 or ≥ 20 points. Charlson Comorbidity Index (CCI) 
focuses on 19 chronic diseases and is well known to pre-
dict mortality. Points are graded by the severity of num-
ber and severity of the disease [13]. It has, since its first 
validation, been adjusted several times in accordance to 
the ICD-9 and ICD-10 [28]. The score is often used in 
geriatric research for examining comorbidity [29]. We 
calculated CCI using ICD-10 codes from 10 years prior 
to individual index admission.
Variables such as height, weight, and the assessment 
of basic ADL were extracted from the Danish National 
Database of Geriatrics. The body mass index (BMI) was 
calculated as weight in kilograms divided by the height 
in meters squared and divided into categories according 
to the WHO definition. In Denmark, assessment of basic 
ADL using Barthel Index is performed upon admission to 
the geriatric departments [8, 9]. The Barthel Index score 
used in the database is the modified version introduced 
by Shah et al.: the Barthel Index-100 [30, 31]. This gath-
ers information across ten areas of basic ADL and sum-
marizes it in a total score. The highest score indicates a 
high level of independence, whereas a low score indicates 
a low level of independence The Barthel Index scores 
were grouped into the four standard categories used in 
Denmark: 0–24, 25–49, 50–79, and 80–100 [8].
Finally, data on death, migration, and marital status 
were extracted from the Danish Civil Registry System.
Statistics
Descriptive statistics are reported as mean with corre-
sponding standard deviation (SD) or median with corre-
sponding inter quartile range (IQR) (25–75% percentile) 
as appropriate. Kaplan–Meier survival curves [32] were 
used to estimate crude survival proportions according to 
each of the number of medications subcategories.
Univariable and multivariable analyses were performed 
using Cox regression [33]. The multivariable analysis 
included adjustment for age, marital status, time period 
of hospitalization, BMI, and Barthel Index (model 1), and 
further adding either number of diseases (model 2) or CCI 
European Geriatric Medicine 
1 3
(model 3). All variables except marital status were included 
as continuous variables in the models. Hazard ratios (HR) 
and corresponding 95% confidence interval (CI) were per-
formed for 30-day, 1-year, and overall mortality.
Furthermore, univariable and multivariable HRs and 
corresponding 95% CI were performed for overall mortal-
ity according to each increase of one medication. Wald 
statistics was used to test for significance of the categori-
cal variables in the multivariable Cox regression model. 
The fully adjusted models were conducted as complete 
case analysis. Analyses were stratified by sex at birth 
according to the health registers. p values < 0.05 indi-
cated statistical significance. Analyses were performed 
by a biostatistician using STATA (version 14.2; StataCorp 
LP, College Station, TX, USA).
Ethics
The Danish data protection agency approved the study 
(2012580018, J.nr. 16/23359). Approval by ethical com-
mittee and informed consent were not necessary according 
to the Danish law on medical ethics due to the register-
based study design.
Results
A total of 74,603 patients (46,823 women and 27,780 men) 
with a median age of 83 (interquartile range [IQR] 77–88) 
years were included in the study. Follow-up ranged from 
1 day to 11 years and 51,197 patients died while none 
were lost to follow-up corresponding to 192,012 person 
years. Median (IQR) survival for the total cohort was 2.66 
(0.64–5.65) years.
The baseline demographics of the study population are 
presented in Table 1. The median (IQR) number of medi-
cations was 6 (4–9), the median (IQR) number of diseases 
was 12 (7–18), and the median (IQR) CCI was 2 (1–3). 
Most patients had low- to moderate reduced ADL with a 
median (IQR) Barthel Index of 54 (29–77).
Survival decreased with increasing number of medica-
tions (Fig. 1) as well as increasing number of diseases 
(Supplementary Fig. 1) and disease severity as expressed 
by increasing CCI (Supplementary Fig. 2).
In the univariable analysis, increasing number of medi-
cations was associated with an increase in overall, 30-day, 
and 1-year mortality (Table 2). The association was higher 
in men compared to women (p < 0.0001). The association 
remained significant in all three models in the multivari-
able analysis (Table 2).
Using number of medications as a continuous vari-
able and “no medications” as the reference, the overall 
risk of dying (HR (95%CI)) during follow-up in the total 
cohort increased by 3.3% (3.0–3.5) for each extra medica-
tion in the univariable analyses (Table 3). In the multi-
variable model adjusting for age, Barthel index, marital 
status, period of hospitalized admission, and BMI each 
extra medication was associated with an increased risk of 
5.0% (4.7–5.3) (model 1). When adding either the num-
ber of diseases or CCI to the multivariable model each 
extra medication was associated with an increased risk of 
3.8% (3.5–4.2) (model 2) and 2.7% (2.4–3.0) (model 3), 
respectively. The risk was significantly higher in men than 
women (p < 0.0001). In a sensitivity analysis patients with 
very high number of medications (20 +) were excluded. 
This did not change the estimates (data not shown).
Discussion
In the present study, we found that increasing number of 
medications is associated with 30-day, 1-year, and overall 
all-cause mortality in geriatric inpatients. To our knowledge, 
this is the largest study assessing the association between 
number of medications and mortality when adjusting for 
ADL and comorbidities.
The present study has several strengths. We were able to 
combine data from the nationwide population-based Danish 
health registers with data on all geriatric inpatients during 
10 years allowing for longitudinal cohort design with no 
patients lost to follow-up. Due to the design, the study had 
no issue with recall bias when addressing prior diseases, use 
of medication, or the objective measurements of ADL. All 
this strengthens the validity of the present study.
However, our study also has some limitations. The study 
did not account for “over-the-counter” medications or the 
patient’s adherence to their medical treatments. We had no 
way to address this further and this could have under- or 
overestimated the demonstrated association between number 
of medications and mortality. Also, the number of diseases 
and CCI was calculated using hospital ICD-10 diagnosis. We 
had no data on ICPC diagnoses [34], which are used by the 
GPs in Denmark as a diagnosis code system for the primary 
healthcare sector. Using hospital ICD-10 diagnoses only to 
define diseases could have underestimated the actual number 
of diseases among the studied population. And in this way, 
we cannot rule out that some of the medications are a marker 
of non-recorded diseases. Also, other important risk factors 
of mortality might have been present at time of index admis-
sion such as delirium. CCI is known to be associated with 
mortality and a prior study has shown high validity when 
using the Danish National Registers to calculate CCI [35]. 
We did adjust for number of known diseases in our model 
2 and disease severity using CCI in model 3. However, the 
present dataset holds no information on actual cognitive 
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Table 1  Baseline characteristics 
of the study population
ATC anatomical therapeutic chemical, BMI body mass index, IQR inter quartile range
*Number of unique diseases was calculated based on hospital discharge diagnoses during ten years before 
baseline. The ICD-10 diagnosis was discriminated at the third level of the ICD-10 code
‡ All redeemed prescriptions were included, except from the following ATC codes: B05x (blood substi-
tutes and perfusion solutions), B06x (other haematological agents), D09x (medicated dressings), J07x (vac-
cines), N01x (anaesthetics) and Vx (various). Medications were counted at the third level of the ATC code, 
i.e. including the first four digits of the ATC code (e.g. Salicylic acid and derivates: N02B). Normal dis-
tributed data are presented with mean (SD) whereas non-normal distributed data are presented with both 
median (IQR) and mean (SD)
Total cohort n = 74,603 Women n = 46,823 Men n = 27,780
Number of drugs purchased 
(120 days) median (IQR)‡
6 (4–9) 6 (4–9) 6 (4–9)
 0 (%) 3.83 3.46 4.45
 1–4 (%) 30.08 29.36 31.29
 5–9 (%) 44.58 45.49 43.04
 ≥ 10 (%) 19.89 20.25 19.29
 Missing (%) 1.62 1.43 1.94
 Diseases (IQR)* 12 (7–18) 12 (7–18) 13 (8–19)
 0 (%) 0.85 0.87 0.81
 1–4 (%) 11.22 11.85 10.16
 5–9 (%) 24.52 25.46 22.93
 ≥ 10 (%) 63.41 61.82 66.10
 Charlson Comorbidity Index 
median (IQR)
2 (1–3) 2 (1–3) 2 (1–4)
 0 (%) 17.66 20.96 12.08
 1 (%) 26.31 28.26 23.02
 2 (%) 21.16 21.24 21.02
 ≥ 3 (%) 34.87 29.53 43.87
 Barthel Index median (IQR) 54 (29–77) 55 (30–77) 52 (26–77)
 80–100 (%) 21.18 21.29 21.00
 50–79 (%) 30.17 31.36 28.18
 25–49 (%) 22.09 22.16 21.98
 0–24 (%) 20.34 19.18 22.29
 Missing (%) 6.21 6.01 6.56
 Age (years) median (IQR) 83 (77–88) 84 (79–89) 81 (76–86)
 65–74 (%) 16.19 13.07 21.45
 75–84 (%) 41.03 39.22 44.08
 85–94 (%) 38.86 42.92 32.03
 ≥ 95 (%) 3.92 4.79 2.44
Marital status (%)
 Unmarried 6.50 5.84 7.62
 Married 29.01 17.66 48.14
 Divorced 12.34 12.31 12.40
 Widowed 52.12 64.17 31.82
 Missing 0.02 0.01 0.03
Period of admission (%)
 2005–2009 42.04 43.64 39.34
 2010–2014 57.96 56.36 60.66
 BMI (kg/m2) mean (SD) 23.93 (5.07) 23.60 (5.26) 24.50 (4.65)
 < 18.5 (%) 9.50 11.64 5.91
 18.5–24.9 (%) 40.37 40.54 40.08
 25–29.9 (%) 20.19 18.50 23.04
 ≥ 30 (%) 8.90 8.75 9.14
 Missing (%) 21.04 20.58 21.83
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status at admission and can, therefore, not be address further. 
Finally, our study along with other similar studies, shares the 
risk of confounding by indication giving the difficulty under-
standing whether medications are associated with increased 
mortality or a proxy for the number and severity of diseases. 
Our approach using different adjustment models to explore 
the impact of medications showed a persistent association 
with increasing number of medications. Despite this, we 
cannot rule out that residual effect might still be present.
Other studies have also reported an association between 
increasing number of medications and mortality [17–20]. 
Most of these studies used the CCI as a measure of disease 
burden [18, 20, 21]. That is, most of the current literature 
used a weighted score to examine the association between 
disease burden and mortality [5]. Only few studies used the 
accumulated unweighted number of diseases, i.e. diagnosis 
count [36, 37]. In a recent systematic review, it was con-
cluded that the Geriatric Index of Comorbidity had a better 
predictive capacity on mortality when compared to other 
comorbidity scores such as CCI and diagnosis count [5]. On 
the other hand, another study showed that diagnosis count 
was a better predictor than the Geriatric Index of Comorbid-
ity [37], although, this might be due to a lesser disease com-
plexity and younger mean age among the studied population 
[37, 38]. In our study, we included adjustment for either 
overall disease burden (diseases count) or disease severity 
(CCI) in the multivariable models and showed that use of 
medications still was associated with mortality.
To our knowledge, three other studies have taken ADL 
in to account when assessing the role of polypharmacy 
on mortality [18, 20, 21]. One study [18] used the SF-36 
physical component score [39] and found that both over-
and-under medication was harmful to the patients. Whereas 
the two others [20, 21] used the Katz index [40]. Wimmer 
et al. found that medication regime was a better predictor 
of all-cause mortality then polypharmacy [20]. Iwata et al. 
found that polypharmacy, defined as > 6 medications, was a 
significant predictor of post-discharge mortality after 1 year 
[21]. The two studies differ in their use of the Katz index 
whereas Wimmer et al. uses all six basic activities, and Iwata 
et al. uses five. It is unclear whether the evaluation of ADL 
was performed via interview/self-reporting or by healthcare 
workers. SF-36 is reported by the patients themselves and 
therefore subject to recall bias. The Katz index covers six 
areas of ADL, whereas Barthel index as used in our study is 
more comprehensive covering ten areas of ADL.
The present study uses ATC classification as a tool to 
measure the number of medications, whereas the three previ-
ously mentioned studies differ on how they obtained data on 
medication (self-reporting and medical records). Although, 
Beer et al. mentioned that the medication used by the partici-
pants in their studies was ATC classified, it is unclear whether 
they used ATC as a tool to measure the number of medica-
tions. Interestingly, Iwata et al. examined different drugs and 
their association with 1-year mortality and found that benzo-
diazepines and NSAIDs were associated with an increased 
risk in mortality. Our study did not examine different types 
of drugs and their association with mortality. We did examine 
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Fig. 1  Kaplan–Meier survival curves total cohort (a), women (b), and 
men (c) stratified by number of medications
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Table 2  Univariable and 
multivariable hazard ratios and 
corresponding 95% confidence 
intervals for overall mortality, 
30 days mortality, and 1-year 
mortality for total cohort (a), 
women (b), and men (c)
Univariable HR (95% CI) Multivariable HR (95% CI)
Model 1 Model 2 Model 3
(a) Total cohort
Overall mortality
 Medications
  0 1 (reference) 1 (reference) 1 (reference) 1 (reference)
  1–4 1.06 (1.01, 1.12) 1.06 (1.01, 1.13) 1.04 (0.98, 1.10) 1.04 (0.98, 1.10)
  5–9 1.26 (1.20, 1.32) 1.31 (1.24, 1.38) 1.21 (1.15, 1.28) 1.17 (1.11, 1.24)
  ≥ 10 1.46 (1.39, 1.54) 1.69 (1.59, 1.78) 1.47 (1.38, 1.55) 1.35 (1.27, 1.42)
30 days mortality
 Medications
  0 1 (reference) 1 (reference) 1 (reference) 1 (reference)
  1–4 1.04 (0.99, 1.10) 1.03 (0.97, 1.08) 1.02 (0.96, 1.07) 1.01 (0.95, 1.07)
  5–9 1.14 (1.08, 1.19) 1.16 (1.09, 1.22) 1.12 (1.06, 1.19) 1.09 (1.03, 1.15)
  ≥ 10 1.20 (1.14, 1.26) 1.32 (1.25, 1.40) 1.25 (1.18, 1.32) 1.17 (1.10, 1.24)
1-year mortality
 Medications
  0 1 (reference) 1 (reference) 1 (reference) 1 (reference)
  1–4 1.05 (1.00, 1.11) 1.03 (0.98, 1.09) 1.02 (0.96, 1.08) 1.01 (0.96, 1.07)
  5–9 1.19 (1.13, 1.25) 1.22 (1.15, 1.29) 1.17 (1.10, 1.23) 1.11 (1.05, 1.17)
  ≥ 10 1.31 (1.24, 1.38) 1.48 (1.40, 1.57) 1.37 (1.29, 1.45) 1.23 (1.16, 1.30)
(b) Women
Overall mortality
 Medications
  0 1 (reference) 1 (reference) 1 (reference) 1 (reference)
  1–4 1.03 (0.96, 1.10) 1.07 (0.99, 1.15) 1.04 (0.96, 1.12) 1.04 (0.96, 1.12)
  5–9 1.21 (1.14, 1.29) 1.33 (1.24, 1.43) 1.24 (1.15, 1.34) 1.20 (1.12, 1.29)
  ≥ 10 1.41 (1.32, 1.51) 1.74 (1.61, 1.88) 1.53 (1.42, 1.66) 1.41 (1.30, 1.52)
30 days mortality
 Medications
  0 1 (reference) 1 (reference) 1 (reference) 1 (reference)
  1–4 1.04 (0.97, 1.11) 1.03 (0.96, 1.11) 1.02 (0.95, 1.10) 1.01 (0.94, 1.09)
  5–9 1.12 (1.05, 1.20) 1.17 (1.09, 1.26) 1.14 (1.06, 1.23) 1.10 (1.03, 1.19)
  ≥ 10 1.19 (1.11, 1.27) 1.34 (1.25, 1.45) 1.29 (1.19, 1.40) 1.20 (1.11, 1.29)
1-year mortality
 Medications
  0 1 (reference) 1 (reference) 1 (reference) 1 (reference)
  1–4 1.03 (0.97, 1.10) 1.04 (0.96, 1.12) 1.02 (0.95, 1.10) 1.02 (0.94, 1.09)
  5–9 1.16 (1.09, 1.24) 1.24 (1.15, 1.33) 1.20 (1.11, 1.29) 1.14 (1.06, 1.23)
  ≥ 10 1.28 (1.19, 1.36) 1.52 (1.40, 1.64) 1.42 (1.32, 1.54) 1.28 (1.18, 1.38)
(c) Men
Overall mortality
 Medications
  0 1 (reference) 1 (reference 1 (reference) 1 (reference)
  1–4 1.15 (1.07, 1.24) 1.13 (1.04, 1.22) 1.11 (1.02, 1.21) 1.10 (1.01, 1.20)
  5–9 1.39 (1.30, 1.50) 1.42 (1.31, 1.54) 1.33 (1.23, 1.45) 1.26 (1.16, 1.37)
  ≥ 10 1.64 (1.52, 1.77) 1.88 (1.72, 2.05) 1.67 (1.53, 1.82) 1.50 (1.37, 1.64)
30 days mortality
 Medications
  0 1 (reference) 1 (reference) 1 (reference) 1 (reference)
  1–4 1.07 (0.99, 1.15) 1.04 (0.96, 1.13) 1.03 (0.95, 1.12) 1.03 (0.94, 1.11)
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the burden of one added drug and the risk of mortality. This 
was not assessed by Iwata et al. or the two other studies.
Other studies assessing medication and mortality have 
focused on specific cut-off points for polypharmacy (≥ 5 
medications) or excessive polypharmacy (≥ 10 medica-
tions) [41, 42]. Our study also assessed the usual cutpoints 
and found an association both with short- and long-term 
survival in the multivariable analysis. In this way, we were 
able to show that burden of medication has both an acute 
and more prolonged negative effect. In the present study, 
we also addressed polypharmacy as a continuous variable 
and found that each medication added to the total burden. 
The overall mortality increased by 3% per medication in the 
fully adjusted model and in this way was associated with 
an increased risk on top of the risk of quantitative number 
of diseases or severe comorbidities. To our knowledge, this 
association has not previously been reported. One explana-
tion of these findings is that drug burden may be a better 
proxy for physiological age than diseases. Another is that 
the results could question whether the geriatric patients in 
this cohort were subject to overtreatment. Whatever the rea-
son, our finding highlights the importance of evaluating the 
medications prescribed to the geriatric patient when admit-
ted to hospital. The results of the current study also empha-
size the importance of ensuring continuously assessment/
monitoring of the medication burden put upon many older 
patients. More in-depth research examining the potential role 
of deprescribing and whether this could affect all-cause sur-
vival is warranted and we recommend that future studies 
should focus on this area.
Model 1: Adjusted for Barthel Index, age, marital status, period of index admission and BMI
Model 2: Adjusted for Barthel Index, age, marital status, period of index admission, BMI, and disease 
count
Model 3: Adjusted for Barthel Index, age, marital status, period of index admission, BMI, and Charlson 
comorbidity index
n = 56,572
n = 35,818
n = 20,754
Table 2  (continued) Univariable HR (95% CI) Multivariable HR (95% CI)
Model 1 Model 2 Model 3
  5–9 1.18 (1.10, 1.27) 1.19 (1.09, 1.29) 1.15 (1.06, 1.25) 1.12 (1.03, 1.21)
  ≥ 10 1.25 (1.16, 1.35) 1.36 (1.25, 1.49) 1.30 (1.19, 1.42) 1.22 (1.12, 1.33)
1-year mortality
 Medications
  0 1 (reference) 1 (reference) 1 (reference) 1 (reference)
  1–4 1.10 (1.02, 1.19) 1.07 (0.98, 1.16) 1.06 (0.97, 1.15) 1.04 (0.96, 1.13)
  5–9 1.27 (1.18, 1.36) 1.28 (1.18, 1.38) 1.23 (1.13, 1.33) 1.16 (1.06, 1.25)
  ≥ 10 1.40 (1.30, 1.51) 1.57 (1.44, 1.72) 1.46 (1.34, 1.60) 1.30 (1.19, 1.42)
Table 3  Univariable and 
multivariable hazard ratios and 
corresponding 95% confidence 
intervals for overall mortality 
according to each increase of 
one medication
Model 1: Adjusted for Barthel Index, age, marital status, period of index admission and BMI
Model 2: Adjusted for Barthel Index, age, marital status, period of index admission, BMI, and disease 
count
Model 3: Adjusted for Barthel Index, age, marital status, period of index admission, BMI, and Charlson 
comorbidity index
n = 54,308 (women 34,535; men 19,773)
Univariable hazard 
ratio (95%CI)
Multivariable hazard ratio (95%CI)
Model 1 Model 2 Model 3
Total cohort 1.033 (1.030, 1.035) 1.050 (1.047, 1.053) 1.038 (1.035, 1.042) 1.027 (1.024, 1.030)
Women 1.031 (1.028, 1.035) 1.053 (1.049, 1.057) 1.043 (1.039, 1.047) 1.032 (1.028, 1.036)
Men 1.038 (1.034, 1.042) 1.057 (1.052, 1.061) 1.047 (1.042, 1.052) 1.035 (1.030, 1.040)
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Conclusion
Increasing number of medications was associated with 
30-day, 1-year, and overall mortality in this nationwide 
cohort of geriatric inpatients. For each extra medication, the 
mortality increased 3% in women and 4% in men in the fully 
adjusted model including ADL and diseases. Our findings 
highlight the importance of the burden of polypharmacy on 
older patients with comorbidities. Future studies are needed 
to address the potential effect of deprescribing on survival 
in these patients.
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